Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ABCL Stock Forecast 2026-2027
$4.01
Current Price
$1.22B
Market Cap
Buy 8
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ABCL Price Targets
+199.3%
To High Target of $12.00
+149.4%
To Median Target of $10.00
+74.6%
To Low Target of $7.00
ABCL Price Momentum
+9.6%
1 Week Change
+17.9%
1 Month Change
+65.7%
1 Year Change
+17.3%
Year-to-Date Change
-38.4%
From 52W High of $6.52
+106.7%
From 52W Low of $1.94
📊 TOP ANALYST CALLS
Did ABCL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if AbCellera is one of their latest high-conviction picks.
Latest ABCL Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, ABCL has a bullish consensus with a median price target of $10.00 (ranging from $7.00 to $12.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $4.01, the median forecast implies a 149.4% upside. This outlook is supported by 8 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Stephen Willey at Stifel, projecting a 199.3% upside. Conversely, the most conservative target is provided by Stephen Willey at Stifel, suggesting a 74.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ABCL Analyst Ratings
8
Buy
1
Hold
0
Sell
ABCL Price Target Range
Low
$7.00
Average
$10.00
High
$12.00
Current: $4.01
Latest ABCL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ABCL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $11.00 |
| Nov 7, 2025 | Leerink Partners | Faisal Khurshid | Market Perform | Downgrade | $4.00 |
| Aug 8, 2025 | Stifel | Stephen Willey | Buy | Maintains | $7.00 |
| Jul 14, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $10.00 |
| Jul 7, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $5.00 |
| May 16, 2025 | Truist Securities | Robyn Karnauskas | Buy | Maintains | $10.00 |
| May 9, 2025 | Stifel | Buy | Maintains | $N/A | |
| Apr 16, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| Mar 3, 2025 | Benchmark | Robert Wasserman | Hold | Reiterates | $N/A |
| Feb 28, 2025 | Stifel | Stephen Willey | Buy | Maintains | $10.00 |
| Jan 8, 2025 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $4.00 |
| Nov 5, 2024 | Stifel | Stephen Willey | Buy | Reiterates | $12.00 |
| Nov 5, 2024 | Benchmark | Robert Wasserman | Hold | Reiterates | $N/A |
| Aug 20, 2024 | Benchmark | Robert Wasserman | Hold | Downgrade | $N/A |
| Jul 11, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $5.00 |
| May 8, 2024 | Keybanc | Scott Schoenhaus | Overweight | Maintains | $7.00 |
| Feb 22, 2024 | Benchmark | Robert Wasserman | Buy | Upgrade | $N/A |
| Feb 21, 2024 | Stifel | Stephen Willey | Buy | Maintains | $17.00 |
| Dec 5, 2023 | Keybanc | Scott Schoenhaus | Overweight | Initiates | $6.00 |
| Oct 13, 2023 | Piper Sandler | Allison Bratzel | Overweight | Assumes | $20.00 |
AbCellera Biologics Inc. (ABCL) Competitors
The following stocks are similar to AbCellera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AbCellera Biologics Inc. (ABCL) Financial Data
AbCellera Biologics Inc. has a market capitalization of $1.22B with a P/E ratio of -8.2x. The company generates $75.13M in trailing twelve-month revenue with a -194.9% profit margin.
Revenue growth is +788.2% quarter-over-quarter, while maintaining an operating margin of -63.7% and return on equity of -14.5%.
Valuation Metrics
Market Cap
$1.22B
Enterprise Value
$825.07M
P/E Ratio
-8.2x
PEG Ratio
-5.1x
Price/Sales
16.2x
Growth & Margins
Revenue Growth (YoY)
+788.2%
Gross Margin
N/A
Operating Margin
-63.7%
Net Margin
-194.9%
EPS Growth
+788.2%
Financial Health
Cash/Price Ratio
+43.9%
Current Ratio
11.3x
Debt/Equity
14.8x
ROE
-14.5%
ROA
-10.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
AbCellera Biologics Inc. (ABCL) Business Model
About AbCellera Biologics Inc.
What They Do
Develops antibody-based medicines for unmet medical needs.
Business Model
AbCellera Biologics operates a clinical-stage biotechnology model focused on discovering and developing therapeutic antibodies. The company generates revenue through strategic collaborations and license agreements with major pharmaceutical companies, leading to milestone payments and royalties as its products progress through clinical trials.
Additional Information
Key programs include ABCL635 for vasomotor symptoms in Phase 2 trials and ABCL575 for autoimmune conditions in Phase 1 trials. AbCellera leverages advanced technologies such as microfluidic cell culture to enhance antibody discovery and development. Founded in 2012 and based in Vancouver, Canada, the company is strategically positioned to address significant health challenges in various medical fields.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
596
CEO
Dr. Carl L.G. Hansen Ph.D.
Country
Canada
IPO Year
2020
Website
www.abcellera.comAbCellera Biologics Inc. (ABCL) Latest News & Analysis
Latest News
Quick Summary
AbCellera will release its Q1 2026 financial results on May 11, 2026.
Why It Matters
AbCellera's upcoming financial results could impact its stock performance and investor sentiment, indicating company health and potential growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
AbCellera Biologics Inc. (ABCL) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
28 days ago
Quick Summary
AbCellera Biologics Inc. (ABCL) presented at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum, indicating continued engagement with investors and the healthcare sector.
Why It Matters
AbCellera's presentation at a major healthcare forum could signal key developments or partnerships, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
1 month ago
Quick Summary
AbCellera Biologics Inc. (ABCL) presented at the TD Cowen 46th Annual Health Care Conference, highlighting its developments and strategies in the healthcare sector.
Why It Matters
AbCellera's presentation at a major healthcare conference signals potential developments in its pipeline, influencing investor sentiment and stock performance in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics Inc. (ABCL) reported its Q4 2025 earnings, detailing financial performance and strategic developments during the quarter. Further specifics were provided in the earnings call transcript.
Why It Matters
The Q4 2025 earnings call for AbCellera Biologics Inc. provides insights into financial performance, growth prospects, and strategic direction, influencing investment decisions and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
AbCellera has reported its full-year business results for 2025, as announced in Vancouver, British Columbia.
Why It Matters
AbCellera's 2025 results provide insights into its financial health and growth trajectory, impacting investor sentiment and future stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AbCellera Biologics Inc. (ABCL) reported a quarterly loss of $0.03 per share, outperforming estimates of a $0.18 loss, and improving from a $0.11 loss a year prior.
Why It Matters
AbCellera's smaller-than-expected loss signals better performance and potential for recovery, which could boost investor confidence and influence stock price positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ABCL Stock
What is AbCellera Biologics Inc.'s (ABCL) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, AbCellera Biologics Inc. (ABCL) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $7.00.
Is ABCL stock a good investment in 2026?
According to current analyst ratings, ABCL has 8 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.01. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ABCL stock?
Wall Street analysts predict ABCL stock could reach $10.00 in the next 12 months. This represents a 149.4% increase from the current price of $4.01. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AbCellera Biologics Inc.'s business model?
AbCellera Biologics operates a clinical-stage biotechnology model focused on discovering and developing therapeutic antibodies. The company generates revenue through strategic collaborations and license agreements with major pharmaceutical companies, leading to milestone payments and royalties as its products progress through clinical trials.
What is the highest forecasted price for ABCL AbCellera Biologics Inc.?
The highest price target for ABCL is $12.00 from Stephen Willey at Stifel, which represents a 199.3% increase from the current price of $4.01.
What is the lowest forecasted price for ABCL AbCellera Biologics Inc.?
The lowest price target for ABCL is $7.00 from Stephen Willey at Stifel, which represents a 74.6% increase from the current price of $4.01.
What is the overall ABCL consensus from analysts for AbCellera Biologics Inc.?
The overall analyst consensus for ABCL is bullish. Out of 14 Wall Street analysts, 8 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ABCL stock price projections?
Stock price projections, including those for AbCellera Biologics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 2:00 AM UTC